Development and Clinical Validation of Liquid Chromatography–Tandem Mass Spectrometry for Measuring Ruxolitinib in Steroid‐Refractory Graft‐Versus‐Host Disease: A First Step Towards Optimized Treatment
The introduction and validation of a liquid chromatography-tandem mass spectrometry method for quantifying plasma RUX concentrations was feasible in our center. Administering predetermined and fixed doses of RUX in patients with SR-GvHD showed highly variable and overlapping plasma drug concentrations. This underscores the potential importance of RUX- pharmacokinetics (PK) monitoring.
Authors
- Mireia Riba (ORCID: https://orcid.org/0000-0002-2409-6946)
- Rodrigo Martino (ORCID: https://orcid.org/0000-0001-5143-4042)
- Jorge Sierra (ORCID: https://orcid.org/0000-0002-7966-0356)
- Miguel Arguello‐Tomas (ORCID: https://orcid.org/0000-0002-3329-4151)
- Irene García‐Cadenas (ORCID: https://orcid.org/0000-0002-2994-9055)
- Edgar Zapico
- Olga Aso (ORCID: https://orcid.org/0000-0001-5452-1854)
- Albert Esquirol (ORCID: https://orcid.org/0000-0002-6062-5980)
- Javier Briones (ORCID: https://orcid.org/0000-0003-2750-3735)
- Sara Redondo (ORCID: https://orcid.org/0000-0001-8967-7410)
- María Costa (ORCID: https://orcid.org/0000-0002-6385-683X)
- Eva Iranzo
Institutions
- Universitat Autònoma de Barcelona (ES)
- Hospital de Sant Pau (ES)
- Josep Carreras Leukaemia Research Institute (ES)
- Universitat Ramon Llull (ES)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1111/ejh.14349
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Instituto de Salud Carlos III